$Lucid Diagnostics(LUCD.US)$Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data From National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard Esophageal Precancer Testing PR Newswire· 2 mins ago
1
2
举报
JESSE JAMES8832 :
would be nice to see this keep going its been in a nice uptrend
$Lucid Diagnostics(LUCD.US)$ NEWS Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing The peer-reviewed publication of positive data from a National Cancer Institute-sponsored study enhances Lucid Diagnostics' reputation and credibility in the medical diagnostics field. EsoGuard's demonstration of unprecedented early precancer detection with 89...
$Lucid Diagnostics(LUCD.US)$Lucid Diagnostics posted Q4 revenues of $1 million, marking a 33% increase from Q3 and a 829% increase annually. Non-GAAP net loss for the quarter was $9.9 million, showing a slight increase from Q3 but a year-over-year decrease of $700,000. The company had a year-end cash balance of $18.9 million, supported by a recent financing of $18.1 million. Approximately 50% of the claims submitted have been adjudicated, with an averaging payment of $1,800. The projected re...
$Lucid Diagnostics(LUCD.US)$Lucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors PR Newswire· 1 min ago The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participants at almost 2.5K per billable test
Lucid Diagnostics股票讨论区
PR Newswire· 2 mins ago
NEWS
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Data from National Cancer Institute-Sponsored, Prospective, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing
The peer-reviewed publication of positive data from a National Cancer Institute-sponsored study enhances Lucid Diagnostics' reputation and credibility in the medical diagnostics field.
EsoGuard's demonstration of unprecedented early precancer detection with 89...
Non-GAAP net loss for the quarter was $9.9 million, showing a slight increase from Q3 but a year-over-year decrease of $700,000.
The company had a year-end cash balance of $18.9 million, supported by a recent financing of $18.1 million.
Approximately 50% of the claims submitted have been adjudicated, with an averaging payment of $1,800.
The projected re...
PR Newswire· 1 min ago
The World Trade Center Health Program will now cover the cost of EsoGuard testing for its more than 120,000 participants at almost 2.5K per billable test
Dow Jones· 1 min ago
5月9日周二,美股集体低开低走,地区银行股指数走低。开盘一小时,道指短暂转涨后再度转跌,纳指跌0.5%与罗素2000小盘股跌近1%均领跌主要指数。
午盘时,标普500指数、道指和纳指均刷新日低,分别跌0.5%、跌近110点和跌0.7%。临近尾盘时道指几度转涨,最终仍与其他指数一同收跌,纳指收盘接近日低。
截至收盘,标普、纳指和纳指100均止步两日连涨,道指连跌两日,纳指失守去年9月12日以来的近八个月最高,纳指100失守去年8月18日以来的近九个月最高:
$标普500指数(.SPX.US)$ 收跌18.95点,跌幅0.46%,报4119.17点。 $道琼斯指数(.DJI.US)$ 收跌56.88点,跌幅0.17%,报33561.81点。 $纳斯达克综合指数(.IXIC.US)$ 收跌77.36点,跌幅0.63%,报12179.55点。 $纳指100ETF-Invesco QQQ Trust(QQQ.US)$ 跌0.7%, ...
By Danilo
$InnovAge Holding(INNV.US)$ $Lucid Diagnostics(LUCD.US)$ $Innovid(CTV.US)$ $切萨皮克能源(CHK.US)$
暂无评论